This expansion now encompasses Merck’s investigational product MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).

Equillium Reports Favorable Interim Results from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease.

Global pharma major Lupin Limited, revealed the introduction of its first biosimilar in Canada, Rymti®, via its collaborator, Sandoz Canada.

Global Pharma major Lupin Limited revealed the completion of an international Phase 3 clinical trial for its biosimilar LUBT010.

On July 26, Belgian biotech company Confo Therapeutics (Confo) announced that it has completed a €60 million Series B financing round.

Levicept Reveals Successful Phase II Trial Results for LEVI-04, a Novel Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis.

On June 24, Viking Therapeutics presented preclinical data of their in-house developed Dual Agonists of Amylin and Calcitonin Receptors (DACARs) .

First Patient Enrolled in US Phase 2 Trial of Akeso’s Ligufalimab and Azacitidine Combo for Myelodysplastic Syndrome.

Genmab A/S revealed that it will take over full responsibilities for both the ongoing development and possible commercialization of acasunlimab.

Rezolute Receives FDA Approval for Phase 3 IND Study of RZ358 for Hypoglycemia Caused by Tumor-Induced Hyperinsulinism.

Aug 8th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Imbrium Therapeutics L.P., has filed an Investigational New Drug Application with the U.S. Food and Drug Administration to assess the use of sunobinop for potentially treating moderate to severe alcohol use disorder.